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REVIEW
Abstract: Topical anesthetics have evolved from a simple solution of cocaine to creams,
ointments, gels, liposomal preparations, and to the latest sophisticated patches and peels.
Topical anesthetics are essential for performing diagnostic, therapeutic, and cosmetic
dermatology procedures. These anesthetics noninvasively deliver anesthesia in locally required
areas. In this review, we present an overview on the mechanism of precutaneous absorption of
skin and address the composition, duration of onset of anesthetic effect, uses, and side effects
that are applicable for the products. Also discussed are the novel advances of using heat to
enhance penetration of the anesthetic as seen in Synera™ patch and delivery of anesthesia
using a peel method as seen in the yet to be US Food and Drug Administration-approved
S-Caine peel.
Keywords: Topical anesthetics, dermal anesthetics, EMLA, iontophoresis, S-Caine Patch,
dentipatch
Introduction
For centuries, topical application of medications has mostly been utilized for the
treatment of localized skin diseases. Topical treatment was meant to treat the disease
state locally with little or no systemic effects
 (Cleary 1984). This review focuses on
the products available for producing the local anesthetic effects necessary for
performing diagnostic, therapeutic, and cosmetic dermatologic procedures.
The first topical anesthetic discovered was cocaine. It was extracted from the
leaves of Erythroxylon coca, a plant originally found in South America
 (Ritchie and
Greene 1980). For centuries the natives had chewed the leaves for their euphoric
effects
 (Dyke and Byck 1982). Nieman first isolated cocaine alkaloid in its pure
form in 1859
 (Fink 1985) and noted its ability to numb the tongue (Faulconor and
Keys 1965), and Koller was the first to use it as a topical anesthetic for eye surgery
(Berger 2000). An ideal topical anesthetic produces effective anesthesia within minutes
when applied to intact skin, has prolonged duration of action, and has minimal side
effects. Another potential benefit of using topical anesthetics is avoiding disruption
of anatomical landmarks. Over the past 150 years, topical anesthetics have evolved
from a simple solution of cocaine to creams, ointments, gels, liposomal preparations,
and to the latest sophisticated patches and peels. Iontophoresis and sonopheresis
have also been utilized to enhance the anesthetic delivery.
Anatomy of skin and percutaneous absorption
Delivery of a drug through the skin is a complex process, and this can be better
appreciated by briefly reviewing the anatomy of the skin. Skin is an effective barrier
and its vital role is to prevent the ingress or egress of compounds across it. When this
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barrier function is compromised for any reason, it results in
loss of body fluids and also becomes a port of entry for
microorganisms into the body as seen in burns patients and
various dermatological conditions. Therefore, skin plays a
key role in protecting the body from various environmental
insults, both biological and chemical (Bucks and Maibach
2002). The skin is composed of the outermost epidermis,
which is avascular, and the dermis, which is vascular, and
which contains the free nerve endings that are responsible
for pain sensation. Hence, the target area for the anesthetic
action is the dermis. The pilosebaceous, apocrine, and
eccrine glands originate in the dermis. These glands
penetrate through the epidermis to reach the surface of the
skin. The dermis is further supported by subcutaneous fat
and muscle beneath. The superficial layer of epidermis is
the stratum corneum. Stratum corneum is almost imper-
meable and responsible for the barrier function of the skin.
It plays a vital role in the absorption of drugs. Stratum
corneum therefore provides the rate-limiting step in the
penetration process (Barry et al 1987).
When a drug is applied to intact skin, it first has to
traverse through the stratum corneum, and to do this, the
drug has to partition from the vehicle into the stratum
corneum. As stratum corneum is lipophilic, usually a drug
in its base form is ideal. The viable part of epidermis and
the dermis are hydrophilic, and the drug has to be in an
ionized state for optimal permeation. When the drug arrives
at the interface of stratum corneum and the viable epidermis,
it has to partition into the hydrophilic tissue. On further
penetration, the drug has to partition into the dermis that is
again hydrophilic. Enroute through the layers of the skin,
the drug undergoes metabolism by enzymes present in the
skin to more active or inactive compounds. Some of the
drug interacts with binding sites forming a depot. The drug
on further penetration reaches subcutaneous tissue and
muscle. These tissues may also act as a depot leading to
sustained release (Schuplein 1978; Flynn 1979; Chien 1982;
Schaefer et al 1982; Guy and Hadgraft 1984; Bronaugh and
Maibach 1985; Marty et al 1985; Bucks et al 2002).
The penetration of drugs through the skin involves
diffusion via transcellular and intercellular pathways, and
via hair follicles and sweat glands. The permeation through
the appendages allows diffusional leakage into the epidermis
and penetration directly into the dermis. This is supposedly
the fastest route for hydrophilic molecules. However, the
major transport pathway is through the intercellular lipid
domains. (Katz and Poulsen 1971; Katz 1973; Poulsen 1973;
Idson 1976; Higuchi 1977).
Transport of an anesthetic depends on its time-scale of
permeation that is either steady state or transient diffusion,
the pKa of the drug, molecular size, stability, binding affinity,
solubility, partition co-efficient, integrity and thickness of
stratum corneum, density of sweat glands and hair follicles,
skin hydration, metabolism, and the vehicle effects (Ranade
and Hollinger 2003). The pKa of an anesthetic is the pH at
which a drug exists both in non-ionic (base) and ionic (salt)
states in equal proportions
 (Covino 1986). As mentioned
earlier, base is the active form that permeates through the
stratum corneum. The closer the pKa of the drug to the pH
of the vehicle and the skin, the more of the drug is in its
active base form and hence its penetration is higher (Schaefer
et al 1982).
For optimizing the percutaneous absorption of topically
applied drugs, two strategies are utilized in formulations.
The first strategy is using a vehicle or device which
maximizes drug delivery into the skin without affecting the
physiochemical properties of stratum corneum and the
second is using penetration enhancers. These enhancers
enter into the skin and alter it reversibly to promote the drug
absorption. An ideal enhancer should be pharmacologically
inert, non-toxic, non-irritating or non-allergenic, and a
suitable solvent for the drug (Woodford and Barry 1986;
Barry et al 1987).
Occlusion is a physical method utilized to enhance the
permeation of the anesthetic through the skin. It impairs
the passive transepidermal loss of water at the site of
application, and increases water content of intercellular
areas. This is responsible for increase in the hydrophilic
character of the stratum corneum, reducing the stratum
corneum–viable epidermis partition coefficient of the
penetrant (Bucks and Maibach 2002).
Mechanism of cutaneous analgesia
The mechanism by which an anesthetic works is by
inhibiting the initiation and propagation of nerve impulses.
This is achieved by the base form of the drug by penetrating
through the axolemma, the outer nerve sheet, and blocking
the influx of sodium ions into the nerve cell, thereby
dampening the generation of action potential.
Product review
EMLA
Eutectic mixture of local anesthetics (EMLA) is based on
an eutectic mixture of two well known local anesthetics
lidocaine and prilocaine. EMLA is an oil-in-water emulsionTherapeutics and Clinical Risk Management 2006:2(1) 101
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mixture. The oil phase consists of the eutectic mixture
lidocaine and prilocaine. A eutectic mixture is one in which
its constituents melt at room temperature and are present in
liquid phase. Broberg when working with emulsion mixtures
had first discovered this property serendipitously. He found
that when lidocaine and prilocaine bases in crystalline form
were mixed together, they became fluid at room temperature.
This is secondary to lowering of the melting points of both
the constituents in the mixture. This effect is best produced
when the drugs were mixed in 1:1 ratio (Juhlin and Evers
1990). With the discovery of eutectic mixture, an oil-in-
water emulsion can be prepared with highest concentration
of the active ingredients (Lycka 1992). In EMLA, the
concentration of lidocaine and prilocaine achieved in the
oil droplet is 80% though the overall concentration of both
the active drugs is kept as low as 5% in the mixture. This is
secondary to the emulsifiers present in the mixture. This
reduction in concentration is responsible for decreased
systemic toxicity (Watson 1986).
Each gram of EMLA is composed of lidocaine 25 mg/ml
and prilocaine 25 mg/ml, polyoxyethylene fatty acid esters
that are emulsifiers, carboxypolymethylene that is a
thickening agent, distilled water with pH adjusted
approximately to 9, and without any preservative
(AstraZeneca 2004). It was released in the US in 1993 and
is Food and Drug Administration (FDA)-approved for use
only on procedures involving intact skin.
EMLA has to be applied under occlusive dressings like
Tegaderm
™, Saran-wrap™, or Band-aid™, which aids
diffusion into the skin (Lycka 1992). The onset of anesthesia
depends on anatomic location and duration of application.
On face and thighs, for needle stick purposes, the onset is
less than 25 minutes (Holmes 1994). For procedures on
mucous membranes involving oral and genitalia, the onset
is in 5–15 minutes without occlusion (Rylander et al 1990).
EMLA does not provide effective anesthesia on thick
glabrous skin like palms and soles and is not recommended
for procedures in these areas (Huang and Vidimos 2000).
The recommended application time for adequate
analgesia is at least 1 hour. For painful procedures like split
skin grafting, the recommended application time is 2 hours
(Lahteenmaki et al 1988). Maximum effect is reached at
2–3 hours of application time and lasts for at least 1–2 hours
after removal (AstraZeneca 2004). In several clinical trials,
EMLA was found to produce adequate dermal analgesia
when applied under occlusive dressing for 60 minutes, and
inadequate analgesia when applied for 30 minutes only
(Evers et al 1985; McCafferty and Woolfson 1993;
Greenbaum and Bernstein 1994). EMLA forms as a depot
in the stratum corneum during occlusion (Evers et al 1985;
Arendt-Nielsen and Bjerring 1988), which results in
continued and even increase in analgesia 15–60 minutes
after removal of the medication (Evers et al 1985; Arendt-
Nielsen and Bjerring 1988; Friedman et al 1999). The onset
of analgesia can be enhanced by pretreatment with low
frequency ultrasound (55 KHz) before application of EMLA
and it was found to be as early as 5 minutes (Katz et al
2004). Rapid onset was also found when EMLA was applied
for 20 minutes with heat (Liu et al 2003).
The duration of analgesia is influenced by the vascularity
of the local area; the more vascular, the more clearance,
and hence the wearing off effect happens sooner. For
example, on the face, the duration of anesthetic effect is
shortened (Arendt-Neilsen et al 1990; Larsson et al 1996).
The depth of an anesthetic effect depends mainly on the
duration of application. When applied for 60 minutes, the
depth of anesthetic effect was found to be 3 mm, and for
120 minutes of application time, the depth of anesthetic
effect was found to be 5 mm (Bjerring and Arendt-Nielsen
1990). In a study evaluating anesthesia for punch biopsies,
EMLA was found to provide effective anesthesia to a depth
of 1–2 mm when applied for 60 minutes, 2–3 mm when
applied for 120 minutes, and 6 mm when applied for 3–4
hours (Wahlgren and Quiding 2000). When EMLA was
applied on intact skin under occlusive dressing and left for
3 hours and 24 hours, the plasma levels of both lidocaine
and prilocaine were found to be well below systemic toxic
level. The peak lidocaine levels were 1/20 and prilocaine
levels were 1/36 of the systemic toxic levels (AstraZeneca
2004). In a study involving 10 patients, when 5–10 g of
EMLA was applied to chronic leg ulcers for a period of
24 hours, plasma concentrations of lidocaine and prilocaine
were found to be less than 1/5th of those associated with
toxic reactions (Stymne and Lillieborg 2001).
In dermatologic procedures, EMLA was found to be
effective in relieving pain associated with shave
 (Shelley
1975) and punch biopsies (Juhlin et al 1980), curettage of
molluscum (Rosdahl et al 1988), split thickness skin grafting
(Goodacre et al 1988), chemical peels (Lycka 1991),
epilation (Hjorth et al 1991), vascular laser treatments
(Ashinoff and Geronemus 1990; Tan and Stafford 1992;
Sherwood 1993), facial laser resurfacing (Ramos-Zabala et
al 2004), laser hair removal (Guardiano and Norwood 2005),
excisional biopsy or curettage, and electro-surgery (Gupta
and Sibbald 1996). EMLA has also been found to be useful
prior to procedures like venepuncture in neonates (HallenTherapeutics and Clinical Risk Management 2006:2(1) 102
Tadicherla and Berman
et al 1984; Kurien et al 1985; Moller 1985), venous
cannulation (Russell and Doyle 1997), lumber puncture
(Kapelushnik et al 1990), sharp wound debrediment, leg
ulcers (Holm et al 1990; Holst and Kristofferson 1998; Lok
et al 1999; Rosenthal et al 2001), decubitus ulcers, abscess
revisions, post-op wounds, diabetic ulcers, burns (Blanke
and Hallern 2003), and post-burn pruritus in children when
applied to newly healing intact skin (Kopecky et al 2001).
EMLA did not provide effective anesthesia for procedures
on external ear (Sarifakioglu et al 2004) As for those on
oral mucosa, EMLA provided anesthesia only for superficial
layers and for short term procedures only (Bernardi et al
1999). EMLA provided comparable anesthesia as LMX for
hair removal with Nd: YAG 1064 nm laser (Guardiano and
Norwood 2005).
Local effects are initial transient blanching followed by
erythema. This is secondary to the bi-phasic effect on
cutaneous blood vessels at the application site. Blanching
is seen in 1.5 hours of application secondary to vaso-
constritive effect (this effect does not favor emergency
venous cannulations), and this is followed by erythema in
2–3 hours of application resulting from vasodilatory effect
(Bjerring et al 1989). Itching and edema can occur. With
repeated applications, local reactions are exacerbated but
resolve after stopping the medication (Evers et al 1985;
Wehle et al 1989). Contact urticaria (Waton et al 2004) and
dermatitis (Ismail and Goldsmith 2005) have also been
reported. Any contact with eye should be avoided as EMLA
irritates the cornea and its high pH 9 may produce lesions
similar to corneal abrasions and ulcerations (Brahma and
Inkster 1995; Eaglstein 1999; McKinlay et al 1999).
Plasma levels where toxic reactions seen are 6 µg/ml. In
studies done in children older than 3 months of age, when
EMLA was applied for 4 hours to intact skin, plasma levels
of lidocaine were shown to be 0.155 µg/ml, and prilocaine
were 0.131 µg/ml, which were well below the toxic levels
(Engberg et al 1987). A well documented major systemic
side effect of using EMLA is methemoglobinemia produced
secondary to prilocaine. This is due to the oxidation of iron
in hemoglobin from ferrous to ferric state, decreasing the
oxygen carrying capacity of hemoglobin. This results in
cyanosis when levels reach around 5%–15% (Russell and
Doyle 1997). EMLA is not recommended in infants younger
than 12 months of age who are on methemoglobinemia-
inducing drugs, patients with glucose-6-phosphate
dehydrogenase (G6PD) deficiency and with congenital or
idiopathic methemoglobinemia (AstraZeneca 2004). It
should be used with caution in infants less than 3 months of
age because of the incomplete maturation of nicotinamide
adenine dinucleotide (NADH)-methemoglobinemia
reductase system (Brisman et al 1998). A maximum of 1 g
for an hour of application is safe on intact skin of term
neonates younger than 3 months (Rincon et al 2000). Central
nervous system (CNS) toxicity was also reported in a toddler
when excessive EMLA was applied over an extensive area
prior to molluscum treatment (Juhlin et al 1989).
Usage of EMLA is contraindicated in the presence of
history of amide sensitivity, liver disease, and skin diseases
like atopic dermatitis, or psoriasis (Juhlin and Rollman
1984). In the later it is secondary to higher rates of absorption
from inflamed areas.
TAC solution
Tetracaine, adrenaline (epinephrine), and cocaine (TAC)
solution is a dermal anesthetic. They are used for open
wounds, such as lacerations and abrasions, to provide anesthetic
effect prior to wound repair. The original formulation of
TAC solution consisted of tetracaine 0.5%, 0.05%
epinephrine 1:2000, and 11.8% cocaine in normal solution.
At this concentration, each ml of TAC solution contains 5 mg
tetracaine, 0.5 mg epinephrine, and 118 mg cocaine. Since 1980,
TAC solution has been used as an alternative to infiltrative
anesthesia with lidocaine for repair of minor superficial
lacerations (Pryor et al 1980; Anderson et al 1990, Huang
and Vidimos 2000). It was found to work better for scalp
and facial lacerations than on extremities (Hegenbarth et al
1990). The same was found when different formulations of
TAC solution were compared (Bonadio and Wagner 1988b;
Smith and Barry 1990; Vinci and Fish 1996). TAC solution
was 95% effective in providing anesthesia prior to repair of
lacerations on face and neck in children, with no adverse
events even on application to an area with a length of 5 cm
and a depth of 5 mm (Bonadio and Wagner 1988a). TAC
solution is applied to the laceration with a cotton ball or
gauze pad soaked in the solution (Grant and Hoffman 1992).
For a laceration up to 5 cm in length, the recommended
dosing of TAC solution is from 2–5 ml. One dosing regimen
is as per weight, 0.09 ml/kg of TAC solution that contains
approximately 10 mg/kg of cocaine (Hegenbarth et al 1990).
Another regimen suggests 1 ml of TAC solution per cm of
laceration (Cannon et al 1989). Application for at least
20 minutes prior to suturing produced effective anesthesia
in children (Ordog and Ordog 1994).
Effectiveness can be determined clinically by visible
blanching (Nichols et al 1987; Hegenbarth et al 1990;
Anderson et al 1990).
 The epinephrine and cocaine in theTherapeutics and Clinical Risk Management 2006:2(1) 103
Percutaneous drugs for local pain control
preparation produce vasoconstriction leading to a prolonged
presence of the drug at the site of application, inhibiting the
absorption of the drugs into systemic circulation, resulting
in fewer systemic effects (Russell and Doyle 1997).
TAC solution is not recommended for usage on mucous
membranes, burn areas, or large abrasions due to the risk of
rapid absorption leading to systemic toxicity. It is also not
recommended for areas supplied by terminal arterioles
(McCafferty et al 1989; Russell and Doyle 1997).
Very low plasma levels of cocaine were detected on
application of 3 ml of TAC solution for 15 minutes in 75%
of children. Tetracaine levels were not detected (Terndrup
et al 1992). Urine drug screen was found to be positive for
cocaine for up to 36–48 hours after usage of TAC solution
(Altieri et al 1990).
Local adverse effects of TAC solution were thought to
be due to the combined vasoconstrictive effects of
epinephrine and cocaine. As a result of this, blood circulation
is decreased at the application site, which leads to a decrease
in tissue defenses. There is a possibility for an increased
risk of wound infection and thereby decreased healing
capacity of the wound (Barker et al 1982; Grant and Hoffman
1992). This could eventually lead to wound dehiscence in
extreme cases (Galvin and De Simone 1976; Gosnold 1977;
Rutherford and Spence 1980; Alkan et al 1984).
 It is also
contraindicated for usages anywhere near the eye area as it
was found to produce corneal abrasions (Bonadio and
Wagner 1990).
Systemic reactions were reported when TAC solution
was applied at or near the mucous membranes. This is
secondary to the rapid and uninhibited absorption of cocaine
and tetracaine from the mucosa. As the individual
components are toxic by themselves, in combination their
toxicities are much more potentiated. Severe adverse events
including respiratory distress, seizures (Wehner and
Hamilton 1984; Tipton et al 1989) and death (Jacobsen 1987;
Dailey 1988) have been reported.
Because of the potential for systemic absorption of
cocaine and resulting side effects, and because cocaine is a
regulated drug, TAC solution is not FDA-approved. New
formulations without cocaine have been tried to compare
their efficacy against TAC solution. At the same
concentrations, TAC without cocaine was found to be less
effective than the original TAC solution (Schaffer 1985).
The same result was found when TAC solution was
compared with tetracaine alone (White et al 1986).
The formulations that were found to be equally effective
as TAC solution are: LAT containing 4% lidocaine,
adrenaline 1:2000, and 1% tetracaine in both children (Ernst
et al 1995a; Schilling et al 1995) and adults (Ernst et al
1995b); lidocaine 5%–epinephrine 1:2000-containing
solution (Blackburn et al 1995); tetraphen containing 1%
tetracaine with 5% phenylephrine (Smith et al 1997); and
bupivanor containing bupivicaine and norepinephrine
(Smith et al 1996). EMLA was found to be superior to TAC,
though EMLA is recommended only for intact surfaces
(Anderson et al 1990).
Amethocaine
Amethocaine is a 4% tetracaine gel and was first synthesized
in 1928 by Eisleb. It has to be applied under occlusive
dressing. Tetracaine is a lipophilic compound and it easily
diffuses through the stratum corneum because of this
property (Covino 1986). This intrinsic property is
responsible for rapid onset of anesthetic effect within
40 minutes (Lawson et al 1995). Due to the same property,
it is held as a reservoir in the skin, which is responsible for
sustained release resulting in a prolonged duration of action
of approximately 4 hours (McCafferty et al 1989). In
dermatology, for pulsed dye laser treatment of port-wine
stains, amethocaine was found to be significantly better in
reducing pain when compared with EMLA (McCafferty et
al 1997). This was a randomized, double-blind and placebo-
controlled study involving 29 patients. The amethocaine
preparation was found significantly better than EMLA,
p < 0.05 by visual analog scale (VAS) pain scoring system
and p < 0.005 by verbal rating score (VRS) pain scoring
system. The results from this study seem to be reliable based
on the p values. It was not found to be effective when
compared with placebo either during or after photodynamic
therapy for small lesions of superficial basal cell carcinoma,
Bowen’s disease or actinic keratosis (Holmes et al 2004).
When compared with placebo, amethocaine gel was
found to provide good analgesic action for skin puncturing
procedural pain in neonates (Moore 2001). When used prior
to minor surgical procedures like venous cannulation in both
adults (Molodecka et al 1994) and children (Lawson et al
1995), amethocaine was found to be as effective as EMLA.
Amethocaine was efficacious for relieving pain prior to
venepuncture in children when compared with placebo (Jain
and Rutter 2000). However, in procedures like heel prick
blood sampling (newborns) (Jain et al 2001), arterial
puncture
 (Tran et al 2002), it was not effective in reducing
pain. For radial artery cannulation in adults, topical
amethocaine provided comparable anesthetic effect as with
lidocaine infiltration (Olday et al 2002).Therapeutics and Clinical Risk Management 2006:2(1) 104
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The most common local effect was erythema. Other
effects were itching and edema, although not commonly
seen (O’Connor and Tomlinson 1995). Secondary to absent
or very low systemic levels upon topical application;
systemic adverse effects are rarely seen. In a study involving
10 subjects on topical application of amethocaine, three
subjects had plasma concentrations of 0.20 mg liter
-1 without
any significant side effects. The absence of side effects was
concluded to be secondary to slow absorption and tissue
hydrolysis of amethocaine after topical dermal application
(Mazumdar et al 1991).
A new micro emulsion formulation of amethocaine in
preclinical studies done in rats was found to be promising
in providing rapid and effective anesthetic effect against heat
and mechanical stimulus when compared with amethocaine
gel, EMLA, lidocaine infiltration, or nothing (Arevalo et al
2004). A novel patch, made of hydroxypropylcellulose discs
containing tetracaine (1 mg × cm
2) and surrounded by a low
tack pressure-sensitive adhesive backing layer was found
to be effective in reducing pain prior to venepuncture in
both term and pre-term infants (Long et al 2004).
LMX (ELA-Max)
LMX is a topical liposomal formulation containing 4% or
5% lidocaine. Liposomes have similar structure as cell
membrane, made up of lipid bi-layers. This structure
enhances the penetration of the drug, leading to rapid onset
of action (Finkel et al 2002) and prevents metabolic
degradation at the application site, which leads to a
prolonged duration of action (Bucalo et al 1998), and also
helps in sustained release of the drug (Yun et al 2002).
LMX 4% is available over the counter and is FDA-
approved for temporary relief of pain and itching associated
with minor cuts, minor burns, sunburn, and insect bites. The
5% preparation needs prescription and has been approved
for anorectal pain. Both the preparations can be used without
occlusion unlike EMLA, but if cooperation is an issue as
faced in pediatrics, LMX can be used under occlusion with
tegaderm and is supplied as 5 g tubes for this purpose. Each
gram of LMX contains lidocaine 40 mg, vitamin E acetate,
propylene glycol, benzyl alcohol, lecithin, cholesterol,
carbomer 940, triethanolamine, polysorbate 80, and purified
water (Huang and Vidimos 2000).
LMX provides effective anesthesia prior to various
procedures when applied for 30 minutes without occlusion
unlike EMLA which needs 60 minutes with occlusion to get
the same effect (Altman and Gildenberg 1999; Eremia and
Newman 2000; Kleiber et al 2002; Eichenfield et al 2002;
Smith and Gjellum 2004; Koh et al 2004). Onset of LMX
has been found to be further enhanced by pretreatment with
erbium: yttrium-aluminum-garnet laser (Yun et al 2002).
In dermatologic procedures, LMX has been tested and
found to be effective as topical anesthetic prior to hair
removal procedures using laser
  (Eremia and Newman 2000)
and high-energy pulsed light source devices (Altman and
Gildenberg 1999). However, both studies lacked good
sample size and blinding. The latter study also did not
involve randomization. In a recent double-blind and
randomized study which evaluated the hair removal using
Nd: YAG 1064 nm laser, both LMX and EMLA showed
similar efficacy in reducing pain when applied for the same
time period of 30 minutes (Guardiano and Norwood 2005).
In a comparative clinical trial with EMLA and placebo
groups for medium-depth chemical peeling involving 10
patients, both LMX and EMLA showed equal efficacy in
reducing the pain when applied for the same period of time
without any clinical or histopathological difference between
the treatment and control group (Koppel et al 2000).
In randomized clinical studies in children comparing
LMX and EMLA, the former was found to be safe and
provided effective anesthesia in 30 minutes prior to
intravenous (IV) insertions (Kleiber et al 2002; Koh et al
2004) and venipuncture (Eichenfield et al 2002). In another
study involving children, LMX provided similar pain and
anxiety reduction during peripheral intravenous (PIV)
insertion in children when compared with injected buffered
lidocaine (Luhmann et al 2004).
LMX has been found to be safe with very minor and
few side effects. The local effects were transient blanching
and erythema. The amount of lidocaine absorbed
systemically depends on the duration and surface area of
application. The recommendation in children is that the area
of application should not be larger than 100 cm2 in a child
weighing less than 10 kg or between 10–20 kg for a single
application of LMX. Systemic effects are seen when plasma
levels of lidocaine are over 5 µg/ml. The serum levels of
lidocaine are in the range of 0.05–0.16 µg/ml when 60 g of
LMX has been applied topically for 3 hours over an area of
400 cm2 of skin (Huang and Vidimos 2000). These levels
are very low when compared with the toxic levels and hence
very low profiles of any serious adverse events were noticed.
As of now, LMX has the advantage of faster onset of
anesthetic effect, no occlusion required, low profile of side
effects, and no risk of methemoglobinemia when compared
with EMLA. More studies are required to establish its
efficacy prior to other dermatologic procedures.Therapeutics and Clinical Risk Management 2006:2(1) 105
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Betacaine–LA
Betacaine LA contains lidocaine, prilocaine, dibucaine, and
phenylephrine (a vasoconstrictor) in petrolatum base. The
exact concentration of the ingredients is not revealed as it is
a proprietary anesthetic. Concentration of lidocaine and
prilocaine are four times that found in EMLA and therefore
should be used cautiously (Friedman, Mafong, et al 2001a).
In adults, betacaine–LA is not recommended to be used
for areas more than 300 cm
2 and is also not recommended
for children (Friedman, Mafong, et al 2001a). It can be
applied without occlusion for 30–45 minutes to get adequate
analgesia. The only comparative study with betacaine–LA
was done under occlusion for 60 minutes, along with EMLA,
LMX, and tetracaine. Anesthetic effect was assessed with
Q-switched Nd: YAG laser at 1064 nm after 60 minutes of
application time and 30 minutes after removal. Its efficacy
was found to be superior to control at the end of 60 minutes,
and 30 minutes after removal of the medication. Both EMLA
and LMX were found to be more efficacious than betacaine–
LA (Friedman et al 1999). However, this is a weak study as
it involves a small sample size (n = 12), lacks randomization,
and involves subjective reporting of pain sensations.
Topicaine
Topicaine contains 4% or 5% lidocaine in a hydro-ethanolic
gel micro emulsion delivery system. It is made up of
lidocaine base 4% or 5% in a gel composed of water, ethanol,
glycerin, jojoba oil, aloe vera oil, glyceryl monolaureate,
benzyl alcohol, carbomer 940, and ethylenediamine
tetraacetic acid (EDTA). Both formulations can be obtained
without prescription.
Four percent topicaine is recommended for usage only
on intact skin under occlusion. Five percent can be used
with or without occlusion. As per manufacturer, topicaine
produces effective analgesic effect when applied for 30–60
minutes prior to a procedure. The recommended maximum
area of application in adults is less than 600 cm
2 and in
children it is less than 100 cm
2.
Topicaine is being used extensively in the field of
cosmetic dermatology. It is indicated for pain relief prior to
procedures like electrolysis, waxing, laser hair removal,
permanent make up, tattoos, collagen injections, botox
injections, hair transplants, laser treatment of telengectiasis,
and acid peels. The 5% formulation can also be used for
anorectal pain relief.
Topicaine’s efficacy was tested in a randomized, double-
blind, controlled trial with EMLA and LMX 5 after
application for 30 minutes with laser-induced pain stimuli
using Q-switched Nd: YAG laser at 1064 nm. Topicaine and
LMX 5 produced effective anesthesia after a 30 minute
application time. However, topicaine and EMLA seemed to
produce the highest anesthetic effect 30 minutes after
removal.
Local effects are mild, which include erythema, edema,
and blanching. Topicaine’s usage is contraindicated in
patients with amide sensitivity. More studies are needed to
establish the efficacy, tolerability and safety profile of
topicaine (Friedman, Mafong, et al 2001b; ESBA 2005).
Iontophoresis
Iontophoresis is a method of enhancing the transport of
topically applied drugs using a mild electric current to
increase the permeability of charged drugs through the skin.
This process is utilized for delivery of drugs like lidocaine,
epinephrine, methylprednisolone succinate, dexamethasone
phosphate, antivirals, and antibiotics (Gangarosa et al 1995).
The drug to be delivered is placed at an electrode of the
same polarity at or near the surface of the treatment area.
The positively charged drug is placed at the anode and the
negatively charged drug is placed at the cathode. A mild
direct current is passed, which travels through the skin,
through the interstitial fluids, and back to the skin, which is
collected by a return electrode. The ions of the drug traverse
through the same path as the current (Gangarosa et al 1995;
Zimmer and Ashburn 2001). Iontophoresis was found to
enhance the penetration of the drug by 20–60-fold when
compared with topical application (Gangarosa et al 1995).
Lidocaine iontophoresis has been found to be 80% to
100% effective in providing anesthetic action prior to
procedures like injections, abrasions, laser surgery, and
cautery. This procedure was not found to be efficacious in
providing enough anesthesia for dermal excisions, for
procedures that involve more than 1cm, and for procedures
done on hands and feet (Maloney et al 1992).
With lidocaine iontophoresis, the onset of action is within
10 minutes. The onset of anesthetic effect was not decreased
by increasing the concentration of lidociane (Oshima et al
1994), and the anesthetic effect lasted for 15 minutes (Kundu
and Achar 2002). The depth of anesthesia was found to be
1–2 cm (Lener et al 1997). The plasma levels of lidocaine
were < 1.0–1 µg/ml after 10 minutes of iontophoresis
application. This did not change even when higher
concentrations of lidocaine were used (Oshima et al 1994).
In dermatologic procedures, iontophoresis has been
found to be a safe and an effective technique for topical
anesthesia in both children and adults. It was found to beTherapeutics and Clinical Risk Management 2006:2(1) 106
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useful for performing procedures in children like shave
biopsy, curettage, injection, punch biopsy (Zempsky and
Parkinson 2003a). This was a multicenter, randomized,
placebo-controlled, double-blind study in 60 children
evaluating the efficacy and safety of lidocaine iontophoresis.
Ninety-four percent in treatment reported no pain when
compared with 7% of patients in the placebo group
(p < 0.001). This is a good quality study and the results seem
to be reliable. It was used in adults prior to performing shave
biopsy (Zempsky and Parkinson 2003b). In this study, 41
patients were evaluated in a single center, randomized,
double-blind, and placebo-controlled fashion. This is a very
good study and the results seem to be reliable as 90% of
patients in the treatment group reported no pain when
compared with 10% of the patients in the placebo group
(p < 0.001). In a comparative clinical study with EMLA, both
provided effective and complete anesthesia, however the
onset of anesthetic effect with iontophoresis had been much
more rapid (within 30 minutes) (Greenbaum and Bernstein
1994). It has also been shown to provide effective anesthesia
prior to pulsed dye laser application of port wine stains
(Nunez et al 1997).
Iontophoresis has also been found to provide rapid and
effective anesthesia in various procedures. It has been found
useful prior to lumbar puncture performed in emergency
department (Strout et al 2004). When compared with placebo
both in children and adults prior to venous cannulation was
found to provide safe and effective anesthesia (Miller et al
2001; Zempsky et al 2004). This was again confirmed in
another study when done in children alone (Rose et al 2002).
In a comparative study with EMLA, iontophotesis was found
to be inferior in efficacy but onset was much faster with
iontophoresis (Squire et al 2000; Moppett et al 2004).
Iontophoresis was also found efficacious for IV placement
(Ashburn et al 1997; Zempsky et al 1998; Galinkin et al
2002), radial artery cannulation (Sherwin et al 2003), and
PIV in both children and adults.
The local effects upon using iontophoresis were transient
erythema and edema, blanching, itching (Zempsky and
Parkinson 2003b; Strout et al 2004), burning, and tingling
sensation. There has been no reported systemic toxicity so
far. The blood levels of lidocaine were found to be below
10 ng/mL without any systemic reactions in a study which
evaluated the tolerability and systemic bioavailability in
pediatric population (Kearns et al 2003). In another
independent study the plasma levels of lidocaine in children
after an average of 20 minutes of iontophoresis with
lidocaine was found to be > 1.0 µg/ml. Less than 1.5 µg/ml
was supposed to be within the normal range (Schultz et al
2002).
Synera™ (S-Caine Patch)
Synera™ is a novel patch system intended to deliver local
anesthesia. This was originally developed under the name
of S-Caine Patch by ZARS Pharma (Salt Lake City, UT,
US), and was recently approved by FDA. It is now licenced
to Endo Pharmaceuticals Inc (Chadds Ford, PA, USA). This
is a lidocaine and tetracaine patch (L/T patch) built in with
a heating element called CHADD (Controlled Heat-Assisted
Drug Delivery), which is a disposable oxygen-activated
system. The L/T patch without the CHADD system has been
found to provide effective anesthetic effect for minor
dermatology procedures in geriatric population (Schecter
2005). The formulation is an emulsion in which the active
ingredients are in oil phase as a eutectic mixture containing
70 mg of lidocaine and 70 mg of tetracaine in a ratio of 1:1
by weight. The inactive ingredients are polyvinyl alcohol,
sorbitan monopalmitate, water, methylparaben, and
propylparaben (Endo Pharmaceuticals Inc. Packet insert for
Synera™). This system does not use any permeation
enhancers. The total surface area of Synera patch is 50 cm2
out of which the active area is 10 cm
2. Synera is indicated
to be used on intact skin for providing local dermal
anesthesia prior to superficial dermatological procedures and
superficial venous access. It is not recommended for usage
on mucous membranes (Endo Pharmaceuticals Inc. Packet
insert for Synera
™).
The CHADD patch uses a new technology that releases
controlled heat to enhance the delivery of the drug. Heat is
generated using a mixture of iron powder, activated carbon,
sodium chloride, wood flour, and water (Endo Pharma-
ceuticals Inc. Packet insert for Synera™). This mixture is placed
in a pouch made of filter paper. This is again sealed between
2 polymer films. One of the films has holes of precalculated
size. Another membrane with tiny holes covers the heat
generating chemical components. When this package is
exposed to atmosphere, air flows through the holes present
in the cover membrane at a controlled rate, into the heating
mixture and initiates a chemical reaction that generates heat.
The amount of heat generated and the duration of reaction
depend on the number and size of the holes in the membrane,
and the composition and amount of the chemicals in the
pouch (See URL: http://www.zars.com/scainepatch.html).
The local anesthetics are packed in a shallow chamber
below the CHADD patch and sealed in an airtight packet.
When applied to the skin, the CHADD patch gets heatedTherapeutics and Clinical Risk Management 2006:2(1) 107
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spontaneously and increases the temperature of the skin,
thereby enhancing the permeation of the drugs through the
epidermis (See URL: http://www.zars.com/scainepatch.html).
This reduces the duration of onset of action of the local
anesthetics. The heating element produces a temperature of
39°C to 41°C for 2 hours (Friedman et al 2001a).
A picture of Synera patch is provided by ZARS on their
website at http://www.zars.com/scainepatch.html (Figure 1).
In a randomized, double-blind study, when Synera was
compared with placebo, prior to minor dermatology
procedures such as skin tag removal, superficial excision,
electrodessication, keloid injection, and shave biopsies
performed in adults, the patch proved to provide safe and
effective anesthesia when applied for 30 minutes (Berman
et al 2005). In a similarly designed study conducted on 74
patients over the age of 65 years, Synera patch-treated
patients had less pain than patients who received placebo
(Endo Pharmaceuticals Inc. Packet insert for Synera
™). The
depth of anesthesia was found to be 6.8 mm with Synera
and 4.7 mm with placebo. The anesthetic effect of the patch
lasted for more than 120 minutes as opposed to 10 minutes
with placebo. This was determined in a randomized, double-
blind, placebo-controlled, two-period crossover trial
involving 12 healthy adult volunteers between the ages of
18 and 50 years. (Shomaker et al 2000). It has also been
found to be beneficial prior to venipuncture in children,
adults, and the geriatric population. In an independent study
among the pediatric population involving 64 children, in a
randomized, double-blind, and placebo-controlled fashion,
Synera was found to be safe and effective when applied for
20 minutes. The child’s pain was rated with the Oucher pain
scale. Seventy-six percent of patients with this medication
had less pain when compared with 20% of patients in the
placebo group (p = 0.001) (Sethna et al 2005). This is a well
balanced study with good sample size and results seem to
be valid.
A 20 minute application of Synera patch showed less
pain in three randomized, double-blind, placebo-controlled
studies that were conducted among adults and the geriatric
population to evaluate the degree of dermal analgesia prior
to venipuncture. Pain was measured using 100 mm visual
analog scale in all three studies. The first study (n = 21)
showed median VAS scores of 1 and 9 for Synera and
placebo treatments, respectively. The second study (n = 40)
showed median VAS scores of 5 and 28 for Synera and
placebo treatments, respectively. The third study (n = 21)
showed median VAS scores of 1 and 9 for Synera and
placebo treatments, respectively. The third study involved
40 subjects over the age of 65 years, and the median VAS
scores for Synera and placebo treatments were 8 and 14,
respectively. In another double-blind study conducted in 250
adult subjects, comparing Synera patch intact with heating
element and without heating element, the median VAS scores
with heating and without heating element were 17 and 22,
respectively (Endo Pharmaceuticals Inc. Packet insert for
Synera
™).
The local effects reported were transient mild erythema,
edema (Sethna et al 2005), blanching (Endo Pharmaceuticals
Inc. Packet insert for Synera
™), and burning sensation
(Berman et al 2005) resolving spontaneously soon after
treatment.
 Contact with the eyes should be avoided as it may
result in severe eye irritation based on animal studies (Endo
Pharmaceuticals Inc. Packet insert for Synera
™). There have
been no reported systemic effects so far. In several studies
conducted in both adults and children, either with a single
or multiple Synera patches, the plasma levels of lidocaine
and tetracaine were well below the toxic levels. Central
nervous system toxicity may usually be seen at levels around
5000 ng/ml, though few patients may show signs of toxicity
like excitation and or depression at plasma lidocaine levels
of approximately 1000 ng/ml. In a study involving adults,
the peak plasma levels of lidocaine were found to be less
than 5 ng/ml, while levels of tetracaine were less than 0.9 ng/
ml in all patients on application of one Synera patch for 30
minutes. When the duration of application was doubled to
60 minutes, there was no significant increase in plasma levels
of both the agents. In children aged 4 months to 12 years,
on application of one Synera patch for 30 min, the plasma
levels of lidocaine and tetracaine were found to be 63 ng/ml
and 65 ng/ml, respectively. Studies were also done to
determine the plasma levels of lidocaine and tetracaine on
simultaneous and sequential usage of multiple Synera
patches in adults and children. Although these studies did
Figure 1 Illustration of Synera patch.
CHADD heating element
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Film for sealing heat
Formulation containing 
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Top cover with holes
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not show the levels of either lidocaine or tetracaine to reach
toxic levels, application of multiple Synera patches is not
recommended. In a clinical pharmacology study, when two
or four Synera patches were applied simultaneously for
60 minutes, the peak plasma concentration of lidocaine were
less than 9 ng/ml, while that of tetracaine were undetectable.
On sequential 30 minute application of four Synera patches
at 60 minute intervals, the peak plasma concentrations of
lidocaine were less than 12 ng/ml and that of tetracaine were
less than the quantitation limit. When two Synera patches
were applied for up to 30 minutes in children of ages
4 months and 12 years, the peak levels of lidocaine and
tetracaine were 331 ng/ml and less than 5 ng/ml, respectively
(Endo Pharmaceuticals Inc. Packet insert for Synera™).
Based on the results of the above mentioned studies, the
usage of Synera patch seems to be safe and without major
side effects. The usage of this patch is not recommended
during magnetic resonance imaging as the heating element
contains iron powder (Endo Pharmaceuticals Inc. Packet
insert for Synera™). The advantages of using Synera over
other topical products are ease of application, heat induced
enhancement of solubility of drugs and their permeation,
no reactions with the vehicle components, and no necessity
for occlusive dressings. (see URL: http://www.zars.com/
scainepatch.html). Most of all, from the data in the above
mentioned studies, Synera patch, when used as recom-
mended by the manufacturer, seems to be very safe and
efficacious in delivering dermal anesthesia. The technique
of using thermal energy for enhancement of drug penetration
may be applied for producing local anesthesia with other
agents as well.
Dentipatch
Dentipatch is an oral transmucosal delivery system
containing lidocaine. This was the first bioadhesive patch
developed for delivering local anesthesia to oral mucosa. It
was introduced in the US in 1996 and is FDA-approved for
providing mild topical anesthesia of accessible mucous
membranes of the mouth prior to superficial dental
procedures (Mantele et al 2005). This patch can also find its
use in dermatology prior to procedures involving oral mucosa.
The dentipatch contains a viscous mixture of lidocaine,
lecithin, propylene glycol, dipropylene glycol, glycerin,
karaya gum, aspartame, and spearmint flavor. This mixture
is coated onto a backing containing a polyster/ethylene vinyl
acetate (EVA) film laminated to a polyester/rayon nonwoven
fabric at a predetermined thickness. This is then dried in
ovens to accelerate gelling process. Once the gelling is
completed, this is again laminated to the release liner. The
current available product contains 46.1 mg of lidocaine which
is 20 weight percent concentration in a bioadhesive matrix.
It provides site-specific anesthetic effect where needed, when
directly applied to the mucosa (Mantele et al 2005).
On application of the dentipatch for 15 minutes,
anesthetic effect was found to be produced in 2.5 minutes,
and the action lasted for 40 minutes after the removal of the
patch. Two studies done to evaluate the efficacy of 10 and
20 weight percent lidocaine patches against placebo showed
to provide effective anesthetic effect when tested with 25
gauge needle inserted unto bone. The plasma levels of
lidocaine with 20 weight percent active patch at intervals of
15 and 45 minutes were found to be 9 times lesser than
those achieved with injection of 2% lidocaine. Plasma levels
of lidocaine with application of 5% lidocaine ointment were
found to be at least double than those achieved with
application of 20 weight percent of dentipatch for the same
time period of 15 minutes. The most common local effect
found was unpleasant taste. The other was minimal irritation
(Hersh et al 1996; Mantele et al 2005).
Other patches
Other patches are also used for their systemic effects in the
management of chronic pain states. One such patch is
duragesic patch containing the opioid, fentanyl. This
provides sustained analgesia around the clock. It finds
application in the treatment of cancer and noncancer pain
states. The lidoderm patch containing lidocaine 5% has been
found to be useful in chronic pain states. It has been
extensively studied and used for pain control in post-herpetic
neuralgia. It has also been studied for pain control in
osteoarthritis, myofascial pain, peripheral pain syndromes,
chronic leg ulcers, allodynia, and erythromelalgia (Katz et
al 2002; Davis 2003; Meier et al 2003; Gammaitoni et al
2003, 2004; Dalpiaz et al 2004).
S-Caine peel
This is a novel and innovative method of delivering topical
anesthesia, mostly is being tested in the field of cosmetic
dermatology. This is a cream-based preparation, made up
of eutectic mixture of lidocaine 7% and tetracaine 7%. The
inactive ingredients in the formulation are polyvinyl alcohol,
lecithin, corn starch, and water (Chen et al 2003). When
applied to the skin, it dries on exposure to air, forming a
flexible membrane that can be easily peeled off. The
advantage is that anesthesia is easily delivered to contours
of the body without needing any occlusion (see URL:Therapeutics and Clinical Risk Management 2006:2(1) 109
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http://www.zars.com/scainepeel.html). Its efficacy had been
mostly tested for anesthesia that is necessary for laser
procedures used in dermatology. A picture of S-Caine peel
is provided by ZARS on their website at http://www.zars.com/
scainepeel.html.
In comparative clinical studies with placebo, it has shown
to provide effective anesthesia, and the time of onset was
between 30 to 60 minutes. The level of anesthetic action
needed depended on the specific type of lasers, such as
pulsed dye laser, nonablative laser, and long-pulsed Nd: YAG
laser, used for specific procedures (Bryan and Alster 2002;
Doshi et al 2003; Jih et al 2004). The more the numbing
effect is needed, the more time the peel should be left behind.
In a randomized, double-blind, placebo-controlled study
involving 60 patients in three centers, S-Caine peel was
found to provide safe and effective anesthesia in 20 to 30
minutes of applicaton prior to treatment of portwine stains
and facial telengectiasis using pulsed dye laser. Fifty-two
percent of patients had VAS scores for pain as 10 mm and
72.2% of patients had VAS scores as 20 mm being on the
active drug. The investigators and independent observer
rated no pain in 75% and 72% of patients on the active drug,
respectively. The high level of efficacy found in this study
should be confirmed by further clinical evaluation (Bryan
and Alster 2002). For treatment of leg veins using long-
pulsed Nd: YAG laser treatment, S-Caine peel provided safe
and highly effective anesthesia when applied for 60 minutes
(Jih et al 2004). This was evaluated in a study involving
60 patients which was a randomized, double-blind, placebo-
controlled study conducted at 2 centers (p < 0.001). In a
multicentered, randomized, double-blind, placebo-
controlled study conducted in 30 adult patients, who
underwent laser-assisted tattoo removal, 70% of patients,
S-Caine peel was found to have pain reduction when applied
for 60 minutes (Chen et al 2005).
Local side effects thus far reported included transient
mild erythema (Bryan and Alster 2002; Doshi et al 2003;
Chen et al 2005). This interesting new invention seems to
have advantages over classical topical anesthetics, in that it
can be easily applied and removed, and the anesthetic effect
generated depends on the duration of the peel left behind.
More information pertaining to plasma levels of the active
agents attained and potential side effects, if any, would be
expected to be available once S-Caine peel is approved by
the FDA.
Summary
Table 1 summarizes the various modes of penetration
enhancements of the drugs discussed in this review.
Conclusion
Among the current available products, EMLA and LMX
have been widely tested and are popular in clinical practice.
With the invention of smaller and portable instruments,
iontophoresis has considerable potential to regain its
popularity. Synera patch, which was recently FDA-
approved, would likely find more application because of its
ease of usage, especially in the pediatric population. In the
immediate future, S-Caine peel has potential to become
popular in cosmetic dermatology procedures.
There has been significant research over the past decade
in understanding the skin permeation mechanisms. The
outcome of research in this area so far is reflected on the
advances we are now seeing in the development of
formulations and devices that optimize drug delivery, either
by passive or active means, necessary for local and or
systemic effects. More products in the form of patches with
novel polymers for constructing the backing membranes and
Table 1 Modes of penetration enhancement
Mode of penetration
Medication Concentration enhancement
EMLA 2.5% lidocaine and ￿ Occlusion
2.5% prilocaine ￿ Eutectic mixture
￿ Emulsion mixture
￿ pH 9.4
LMX 4% or 5% lidocaine ￿ Liposomal carriage
Amethocaine 4% tetracaine ￿ Occlusion
gel ￿ Intrinsic lipophilic
   property
Betacaine–LA Lidocaine, prilocaine, ￿ Emulsion system
dibucaine, and
phenylephrine
Topicaine 4% 4% lidocaine ￿ Occlusion
Topicaine 5% 5% lidocaine ￿ With/without occlusion
￿ Micro-emulsion delivery
   system
Synera
™ patch Lidocaine 70 mg and ￿ Occlusive effect of
tetracaine 70 mg    patch
￿ Self heating element
S-Caine peel 7% lidocaine and ￿ Occlusive effect
7% tetracaine    resulting from the
   formation of tight
   flexible film over site of
   application.
TAC solution 0.5% tetracaine, ￿ Passive diffusion
or gel 0.05% epinephrine 1:2000,
and cocaine 11.8%
Iontophoresis Charged drugs like ￿ Driven by electric
lidocaine.    current gradient
Abbreviations: EMLA, Eutectic mixture of local anesthetics; TAC, tetracaine,
adrenaline, and cocaine.Therapeutics and Clinical Risk Management 2006:2(1) 110
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adhesives, peels, and vesicles as drug carriers are likely to
be the mode of drug delivery through the skin in future.
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